Lilly's public pipeline table lists brenipatide, macupatide and a long-acting GIPR agonist

Eli Lilly's public pipeline table, dated August 5, 2026, lists several new molecules beyond its approved GLP-1 drugs Mounjaro, Zepbound, and the oral drug Foundayo (orforglipron) ^[1]. Among them are brenipatide and macupatide, along with a long-acting GIP receptor agonist and an obesity drug called eloralintide, which is being tested for several conditions ^[1].

Eloralintide, listed as a new molecular entity, is in Phase 3 testing for obesity ^[1]. The pipeline also lists eloralintide in Phase 3 for obstructive sleep apnea and osteoarthritis pain, plus a separate "Eloralintide Incretin Add-On" program in Phase 3 for obesity ^[1]. The source does not describe how eloralintide works or give trial results.

Brenipatide appears far more often on the list than any single-indication drug. It is in Phase 3 for alcohol use disorder and major depressive disorder ^[1]. It is also in Phase 2 for asthma, bipolar disorder, irritable bowel syndrome with constipation, irritable bowel syndrome with diarrhea, opioid use disorder, schizophrenia, and tobacco use disorder ^[1]. These entries fall under Lilly's neuroscience and immunology categories, not its cardiometabolic health group, where the company's diabetes and obesity drugs are listed ^[1].

Macupatide is listed only once, as a new molecular entity in Phase 2 for obesity, under the cardiometabolic health category ^[1]. A separate large-molecule program called "GIPR Agonist Long Acting" is in Phase 2 for chemotherapy-induced nausea and vomiting, listed under Lilly's cancer therapeutic area rather than cardiometabolic health ^[1].

The same pipeline table also shows tirzepatide (Mounjaro/Zepbound) in Phase 3 testing for type 1 diabetes, metabolic dysfunction-associated steatotic liver disease, and a "morbidity and mortality in obesity" outcomes study, plus a cardiovascular outcomes program already in regulatory review ^[1]. Orforglipron (Foundayo) is listed in Phase 3 for cardiovascular outcomes, hypertension, obstructive sleep apnea, osteoarthritis pain, peripheral artery disease, and stress urinary incontinence, with a diabetes indication already in regulatory review ^[1].

Why it matters for patients

None of these listed programs are approved drugs. Lilly's own disclaimer says pipeline molecules can be discontinued or delayed at any point, and that reaching this list is no guarantee a drug will ever reach pharmacy shelves ^[1]. For someone currently using Ozempic, Wegovy, Mounjaro, or Zepbound, the pipeline table does not signal any near-term change to available treatments.

What the list does show is that Lilly is testing molecules related to its incretin drugs for conditions well outside diabetes and obesity, including addiction, mood disorders, and bowel disease. It also shows a separate long-acting GIP-only drug being tested for a very different use, nausea during chemotherapy, rather than for weight loss or blood sugar ^[1]. The pipeline does not explain why these molecules are being tested this way or what data supports moving them forward.

The source lists indications and trial phases but does not include dosing, safety data, or trial results for any of these newer molecules ^[1]. That means what these drugs actually do in patients, and whether they work, is not yet known from this source.

What happens next

Lilly says the pipeline reflects data as of August 5, 2026, and the company "assumes no duty to update this information" going forward ^[1]. No specific dates for trial completions, readouts, or regulatory filings for brenipatide, macupatide, or the long-acting GIP agonist are given in the source ^[1]. Phase 1 details for any earlier-stage molecules are not disclosed at all ^[1].